---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-037125"
form_type: "8-K"
ticker: "DNTH"
cik: "0001690585"
company_name: "Dianthus Therapeutics, Inc. /DE/"
filed_at: "2025-03-11T23:59:59+00:00"
generated_at: "2026-05-24T23:47:04.373767+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Dianthus reports FY2024 net loss $85M; Phase 2 gMG top-line on track for 2H'25

## Summary
- Net loss of $85.0M ($2.55 per share) in FY2024, vs $43.6M ($8.45 per share) in FY2023.
- Cash, cash equivalents and investments of $357.0M as of Dec 31, 2024, providing runway into 2H'27.
- R&D expenses rose to $83.1M from $32.8M, driven by clinical and CMC costs for DNTH103.
- Phase 2 MaGic gMG trial on track for top-line results in 2H'25; Phase 3 CIDP interim analysis in 2H'26.
- Appointed John C. King as CCO and Sujay Kango to Board on March 5, 2025.

## SEC filing metadata
- accession: 0000950170-25-037125
- form_type: 8-K
- ticker: DNTH
- cik: 0001690585
- company_name: Dianthus Therapeutics, Inc. /DE/
- filed_at: 2025-03-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1690585/000095017025037125/0000950170-25-037125-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1690585/000095017025037125/dnth-20250311.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-037125
- JSON: https://secwatch.observer/filing/0000950170-25-037125.json
- Plain text: https://secwatch.observer/filing/0000950170-25-037125.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.